Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accumulated Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Accumulated Expenses for 16 consecutive years, with $83.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed N/A to $83.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $83.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $83.3 million for FY2025, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2025 was $83.3 million at Cytokinetics, up from $33.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $83.3 million in Q4 2025, with the low at $7.0 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $29.7 million, with a median of $22.4 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses surged 321.88% in 2022, then crashed 53.68% in 2023.
  • Over 5 years, Accumulated Expenses stood at $14.9 million in 2021, then skyrocketed by 45.79% to $21.8 million in 2022, then soared by 95.9% to $42.6 million in 2023, then increased by 16.85% to $49.8 million in 2024, then soared by 67.14% to $83.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $83.3 million, $33.2 million, and $52.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.